tetano
Editor, Senior Moderator
J Radiat Oncol
. 2020 Sep 29;1-3.
doi: 10.1007/s13566-020-00436-w. Online ahead of print.
Early detection of SARS-CoV-2 from staging PET-CT
Mohamed H Khattab[SUP] 1 [/SUP], Alexander D Sherry[SUP] 2 [/SUP], Aaron C Jessop[SUP] 3 [/SUP], Kristen K Ciombor[SUP] 4 [/SUP], Bapsi Chakravarthy[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: SARS-CoV-2 infection may manifest with minimal or no clinical symptoms. However, signs of infection may appear on routine imaging obtained in the care of patients with cancer. The management of patients planned for chemoradiation with asymptomatic or mildly symptomatic SARS-CoV-2 infection is uncertain.
Methods: Here, we present a case study of a mildly symptomatic patient with anal cancer diagnosed with SARS-CoV-2 from a staging PET-CT scan.
Results: PET-CT scan for anal cancer staging demonstrated pulmonary avidity suspicious for an infectious, rather than malignant, process. In the setting of these imaging findings and new-onset anosmia, viral polymerase chain reaction was ordered and found to be positive for SARS-CoV-2. To avoid myelosuppression in the setting of active infection, planned chemoradiation was delayed until cessation of viral shedding.
Conclusion: In the COVID-19 era, oncologists obtaining routine staging imaging should have high diagnostic suspicion for subclinical SARS-CoV-2 infection. To avoid precipitating severe pneumonia and hospitalization, multidisciplinary discussion with risk-benefit analysis is recommended before initiating immunosuppressive therapies such as chemoradiation.
Keywords: Anal cancer; COVID-19; Cancer staging; Chemoradiation; Coronavirus.
. 2020 Sep 29;1-3.
doi: 10.1007/s13566-020-00436-w. Online ahead of print.
Early detection of SARS-CoV-2 from staging PET-CT
Mohamed H Khattab[SUP] 1 [/SUP], Alexander D Sherry[SUP] 2 [/SUP], Aaron C Jessop[SUP] 3 [/SUP], Kristen K Ciombor[SUP] 4 [/SUP], Bapsi Chakravarthy[SUP] 1 [/SUP]
Affiliations
- PMID: 33014283
- PMCID: PMC7524033
- DOI: 10.1007/s13566-020-00436-w
Abstract
Objective: SARS-CoV-2 infection may manifest with minimal or no clinical symptoms. However, signs of infection may appear on routine imaging obtained in the care of patients with cancer. The management of patients planned for chemoradiation with asymptomatic or mildly symptomatic SARS-CoV-2 infection is uncertain.
Methods: Here, we present a case study of a mildly symptomatic patient with anal cancer diagnosed with SARS-CoV-2 from a staging PET-CT scan.
Results: PET-CT scan for anal cancer staging demonstrated pulmonary avidity suspicious for an infectious, rather than malignant, process. In the setting of these imaging findings and new-onset anosmia, viral polymerase chain reaction was ordered and found to be positive for SARS-CoV-2. To avoid myelosuppression in the setting of active infection, planned chemoradiation was delayed until cessation of viral shedding.
Conclusion: In the COVID-19 era, oncologists obtaining routine staging imaging should have high diagnostic suspicion for subclinical SARS-CoV-2 infection. To avoid precipitating severe pneumonia and hospitalization, multidisciplinary discussion with risk-benefit analysis is recommended before initiating immunosuppressive therapies such as chemoradiation.
Keywords: Anal cancer; COVID-19; Cancer staging; Chemoradiation; Coronavirus.